Phreesia (NYSE:PHR) Price Target Raised to $34.00 at Piper Sandler

Key Points

• Investment analysts at Piper Sandler raised Phreesia's target price from $33.00 to $34.00, suggesting an 8.61% potential upside.
• Phreesia reported a 14.9% increase in quarterly revenue compared to the same period last year, totaling $117.26 million, and beat EPS estimates by $0.08.
• Thirteen research analysts currently rate Phreesia with a "Buy" rating, with a consensus target price of $33.00.

Phreesia (NYSE:PHR - Get Free Report) had its price target upped by stock analysts at Piper Sandler from $33.00 to $34.00 in a research report issued on Friday, MarketBeat.com reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's price objective would indicate a potential upside of 32.03% from the stock's previous close.

A number of other equities research analysts also recently weighed in on PHR. KeyCorp lifted their price target on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Truist Financial increased their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Citigroup restated a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Stephens reaffirmed an "overweight" rating and set a $32.00 price objective on shares of Phreesia in a research report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of "Buy" and an average price target of $34.08.

Phreesia Stock Down 3.0%

NYSE PHR traded down $0.80 on Friday, hitting $25.75. 575,191 shares of the company were exchanged, compared to its average volume of 570,816. The stock has a fifty day moving average of $28.27 and a 200-day moving average of $26.50. Phreesia has a 12 month low of $17.07 and a 12 month high of $32.76. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.53 billion, a PE ratio of -61.40 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings data on Thursday, September 4th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The firm had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same period in the prior year, the business posted ($0.03) earnings per share. The company's quarterly revenue was up 14.9% compared to the same quarter last year. Phreesia has set its FY 2026 guidance at EPS. As a group, analysts forecast that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, SVP David Linetsky sold 23,729 shares of Phreesia stock in a transaction on Friday, June 27th. The shares were sold at an average price of $28.50, for a total value of $676,276.50. Following the transaction, the senior vice president owned 193,510 shares in the company, valued at $5,515,035. This trade represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark Douglas Smith sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total value of $203,000.00. Following the sale, the director owned 37,353 shares in the company, valued at $1,083,237. The trade was a 15.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,292 shares of company stock valued at $3,295,323 in the last ninety days. 5.50% of the stock is owned by insiders.

Institutional Trading of Phreesia

A number of hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. raised its holdings in Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company's stock valued at $400,000 after buying an additional 375 shares in the last quarter. Diversified Trust Co grew its holdings in Phreesia by 1.0% during the 2nd quarter. Diversified Trust Co now owns 45,042 shares of the company's stock worth $1,282,000 after acquiring an additional 426 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Phreesia by 2.8% during the second quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company's stock worth $569,000 after acquiring an additional 540 shares in the last quarter. Arcadia Investment Management Corp MI raised its stake in shares of Phreesia by 0.7% in the 1st quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company's stock valued at $2,371,000 after purchasing an additional 615 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its position in Phreesia by 9.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company's stock valued at $251,000 after purchasing an additional 792 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.